With the establishment of the efficacy of antibody-drug conjugate (ADC) in HER2-low expression breast cancer patients, HER2-low expression may become a new targeted therapeutic subtype of breast cancer, and the novel ADC has become a new therapeutic option for HER2- low expression advanced breast cancer patients (7). Here, ERBB2 is linked to breast cancer.